argenx to Report First Quarter 2023 Financial Results and Business Update on May 4, 2023

Rhea-AI Summary

argenx (Euronext & Nasdaq: ARGX) will host a conference call and audio webcast on May 4, 2023, at 2:30 pm CET to discuss its first quarter 2023 financial results and provide a business update. The event will be available via the Investors section of their website. A replay will be accessible for one year. Dial-in numbers are provided for various countries including the U.S., U.K., and Japan.

As a global immunology company, argenx is focused on severe autoimmune diseases and has partnered with researchers through its Immunology Innovation Program. The company is currently evaluating the therapeutic potential of its approved neonatal Fc receptor (FcRn) blocker and advancing several experimental medicines.

Positive

• Hosting a conference call to discuss Q1 2023 financial results indicates transparency and engagement with investors.
• Continued development of efgartigimod reflects positive progress in treating severe autoimmune diseases.

Negative

• None.

April 27, 2023

Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, May 4, 2023 at 2:30 pm CET (8:30 am ET) to discuss its first quarter 2023 financial results and provide a business update.

A webcast of the live call may be accessed on the Investors section of the argenx website at argenx.com/investors. A replay of the webcast will be available on the argenx website for approximately one year following the presentation.

Dial-in numbers:

Use the access code 3810049 to join the call. Please dial in 15 minutes prior to the live call.

Belgium                32 800 50 201
France                        33 800 943355
Netherlands                31 20 795 1090
United Kingdom        44 800 358 0970
United States                 1 888 415 4250
Japan                        81 3 4578 9752
Switzerland                41 43 210 11 32

About argenx

argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first-and- only approved neonatal Fc receptor (FcRn) blocker in the U.S., Japan, the EU and the UK. The Company is evaluating efgartigimod in multiple serious autoimmune diseases and advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visit https://www.argenx.com and follow us on LinkedIn, Twitter, and Instagram.

For further information, please contact:

Media:

Erin Murphy
emurphy@argenx.com

Investors:

Beth DelGiacco
bdelgiacco@argenx.com

FAQ

When will argenx announce its first quarter 2023 financial results?

argenx will announce its first quarter 2023 financial results on May 4, 2023.

How can investors listen to the argenx conference call?

Investors can access the conference call via the Investors section of the argenx website.

What is the significance of the upcoming conference call for ARGX investors?

The conference call will provide insights into the financial performance and business updates crucial for ARGX investors.